Indication example (id = "example-indication")

<?xml version="1.0" encoding="UTF-8"?>

<ClinicalUseDefinition xmlns="http://hl7.org/fhir">
  <id value="example-indication"/> 
      <!--    example product is indicated for Prevention of venous thromboembolic events,
   in adults (18+)    -->
      <!--    product is for 18 years and above    -->
  <text> <status value="extensions"/> <div xmlns="http://www.w3.org/1999/xhtml"><p> <b> Generated Narrative: ClinicalUseDefinition</b> <a name="example-indication"> </a> <a name="hcexample-indication"> </a> </p> <div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border:
       1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource ClinicalUseDefinition &quot;example-indication&quot; </p> </div> <p> <b> StructureDefinition Work Group</b> : brr</p> <p> <b> type</b> : indication</p> <p> <b> subject</b> : <a href="medicinalproductdefinition-example.html">MedicinalProductDefinition/example</a> </p> <blockquote> <p> <b> indication</b> </p> <h3> DiseaseSymptomProcedures</h3> <table class="grid"><tr> <td style="display: none">-</td> <td> <b> Concept</b> </td> </tr> <tr> <td style="display: none">*</td> <td> Prevention of venous thromboembolic events (VTE) in adult patients who have undergone
               elective hip or knee replacement surgery. Prevention of stroke and systemic embolism
               in adult patients with non-valvular atrial fibrillation (NVAF), with one or more
               risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75
               years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥
               II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention
               of recurrent DVT and PE in adults. <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (indicationasdisease-symptom-procedure#Pulmonary-embolism-and-thrombosis-example-code)</span> </td> </tr> </table> <h3> DiseaseStatuses</h3> <table class="grid"><tr> <td style="display: none">-</td> <td> <b> Concept</b> </td> </tr> <tr> <td style="display: none">*</td> <td> Recurrent <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (diseasestatus#Recurrent)</span> </td> </tr> </table> <h3> IntendedEffects</h3> <table class="grid"><tr> <td style="display: none">-</td> <td> <b> Concept</b> </td> </tr> <tr> <td style="display: none">*</td> <td> PRYLX <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (intendedeffect#PRYLX)</span> </td> </tr> </table> </blockquote> <p> <b> population</b> : <a name="hcgroup"> </a> </p> <blockquote> <p/>  <p> <a name="group"> </a> </p> <p> <a name="hcgroup"> </a> </p> <p> <b> type</b> : person</p> <p> <b> membership</b> : definitional</p> <h3> Characteristics</h3> <table class="grid"><tr> <td style="display: none">-</td> <td> <b> Code</b> </td> <td> <b> Value[x]</b> </td> <td> <b> Exclude</b> </td> </tr> <tr> <td style="display: none">*</td> <td> age-range <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (characteristic#age-range)</span> </td> <td> 18-? a</td> <td> false</td> </tr> </table> </blockquote> <hr/>  <blockquote> <p> <b> Generated Narrative: Group #group</b> <a name="group"> </a> <a name="hcgroup"> </a> </p> <p> <b> type</b> : person</p> <p> <b> membership</b> : definitional</p> <h3> Characteristics</h3> <table class="grid"><tr> <td style="display: none">-</td> <td> <b> Code</b> </td> <td> <b> Value[x]</b> </td> <td> <b> Exclude</b> </td> </tr> <tr> <td style="display: none">*</td> <td> age-range <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (characteristic#age-range)</span> </td> <td> 18-? a</td> <td> false</td> </tr> </table> </blockquote> </div> </text> <contained> 
    <Group> 
      <id value="group"/> 
      <type value="person"/> 
      <membership value="definitional"/> 
      <characteristic> 
        <code> 
          <coding> 
            <system value="http://ema.europa.eu/example/characteristic"/> 
            <code value="age-range"/> 
          </coding> 
        </code> 
        <valueRange> 
          <low> 
            <value value="18"/> 
            <unit value="a"/> 
          </low> 
        </valueRange> 
        <exclude value="false"/> 
      </characteristic> 
    </Group> 
  </contained> 
  <extension url="http://hl7.org/fhir/StructureDefinition/structuredefinition-wg"><valueCode value="brr"/> </extension> 
  <publisher value="HL7 International / Biomedical Research and Regulation"/> 
  <contact> 
    <telecom> 
      <system value="url"/> 
      </telecom> 
  </contact> 
  <type value="indication"/> 
  <subject> 
    <reference value="MedicinalProductDefinition/example"/> 
  </subject> 
      <!--    example product is indicated for Prevention of venous thromboembolic events
      -->
  <indication> 
    <diseaseSymptomProcedure> 
      <concept> 
        <coding> 
          <system value="http://ema.europa.eu/example/indicationasdisease-symptom-procedure"/> 
          <code value="Pulmonary-embolism-and-thrombosis-example-code"/> 
        </coding> 
        <text value="Prevention of venous thromboembolic events (VTE) in adult patients who have undergone
         elective hip or knee replacement surgery. Prevention of stroke and systemic embolism
         in adult patients with non-valvular atrial fibrillation (NVAF), with one or more
         risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75
         years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥
         II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention
         of recurrent DVT and PE in adults."/> 
      </concept> 
    </diseaseSymptomProcedure> 
    <diseaseStatus> 
      <concept> 
        <coding> 
          <system value="http://ema.europa.eu/example/diseasestatus"/> 
          <code value="Recurrent"/> 
        </coding> 
      </concept> 
    </diseaseStatus> 
    <intendedEffect> 
      <concept> 
        <coding> 
          <system value="http://ema.europa.eu/example/intendedeffect"/> 
          <code value="PRYLX"/> 
        </coding> 
      </concept> 
    </intendedEffect> 
  </indication> 
  <population> 
    <reference value="#group"/> 
  </population> 
</ClinicalUseDefinition>